Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-02
2011-08-02
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07989419
ABSTRACT:
Pharmaceutical compositions for nasal administration to humans, or to warm-blooded animals, comprise: (A) a therapeutically effective amount of insulin; (B) a permeation enhancer; and (C) a liquid carrier; the compositions being further comprised of, or characterized by, any, or each, of: (D) a combination of non-ionic surfactants; wherein the combination of non-ionic surfactants comprises: (i) at least one fatty acid ester of a sugar or sugar alcohol and (ii) at least one pegylated fatty acid ester of a sugar or sugar alcohol; (E) an acidic pH, but no greater than a pH of 4.5; and (F) an osmolality of <200 mOsmol/Kg H2O.
REFERENCES:
patent: 5023252 (1991-06-01), Hseih
patent: 5731303 (1998-03-01), Hsieh
patent: 7112561 (2006-09-01), Gyurik et al.
patent: 7244703 (2007-07-01), Gyurik et al.
patent: 2004/0176476 (2004-09-01), Gyurik
patent: 2005/0123592 (2005-06-01), Gyurik et al.
patent: 2005/0232867 (2005-10-01), Gyurik et al.
patent: 2007/0010425 (2007-01-01), Gyurik et al.
patent: 2007/0265191 (2007-11-01), Gyurik et al.
patent: 2008/0045446 (2008-02-01), Gyurik et al.
patent: 2008/0045447 (2008-02-01), Gyurik et al.
patent: 2008/0107735 (2008-05-01), Gyurik et al.
patent: 2009/0156464 (2009-06-01), Gyurik et al.
patent: 2009/0286715 (2009-11-01), Gyurik
Heinemann et al. “Time-Action Profile of the Long-Acting Insulin Analog Insulin Glargine (HOE901) in Comparison With Those of NPH Insulin and Placebo,” Diabetes Care 23:644-649, 2000.
FDA label for LANTUS (insulin glargine) printed Dec. 4, 2009.
Berg et al. (Biochemistry 5th Ed. 2002, Appendix: pKa Values of Some Acids).
Electronic Supplementary Material for CrystEngComm, The Royal Society of Chemistry (2005, Supplementary material—list of pharmaceutically acceptable acids).
Joint FAO/WHO Expert Committee on Food Additives (JECFA) entry on sorbitan monolaurate printed Dec. 4, 2009.
Hua et al., “Mechanism of Insulin Fibrillation: The Structure of Insulin Under Amyloidogenic Conditions Resembles a Protein-Folding Intermediate,” J. Biol. Chem. May 14, 2004, vol. 279, No. 20; pp. 21449-21460.
Nielsen et al., “Effect of Environmental Factors on the Kinetics of Insulin Fibril Formation: Elucidation of the Molecular Mechanism,” Biochemistry. 2001, vol. 40, No. 20; pp. 6036-6046.
Nielsen et al., “Probing the Mechanism of Insulin Fibril Formation with Insulin Mutants,” Biochemistry. 2001, vol. 40, No. 28; pp. 8397-8409.
International Search Report for international application No. PCT/US07/13512 issued by the International Searching Authority mailed on May 27, 2008.
Written Opinion for international application No. PCT/US07/13512 issued by the International Searching Authority mailed on May 27, 2008.
Gyurik Robert J.
Reppucci Carl
Bradley Christina
CPEX Pharmaceuticals, Inc.
Davitz Michael A.
LandOfFree
Insulin composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Insulin composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2771434